Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Catalyst Pharmaceutical Partners Inc Receives Breakthrough Therapy Designation From FDA For Firdapse For Treatment Of LEMS

Tuesday, 27 Aug 2013 08:03am EDT 

Catalyst Pharmaceutical Partners Inc announced that investigational product Firdapse (amifampridine phosphate) has received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse is Catalyst's investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.